These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 648078)

  • 21. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease.
    Sanjay S; Annigeri RA; Seshadri R; Rao BS; Prakash KC; Mani MK
    Nephrology (Carlton); 2008 Jun; 13(3):247-50. PubMed ID: 18315706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function.
    Aronoff G; Brier M; Mayer ML; Barbalas M; Aogaichi K; Sloan R; Brazzell R; Massarella J
    J Clin Pharmacol; 1991 Jan; 31(1):38-44. PubMed ID: 2045527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.
    Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1983 Dec; 11(6):623-40. PubMed ID: 6678312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
    Dussol B; Morange S; Loundoun A; Auquier P; Berland Y
    Nephrol Dial Transplant; 2006 Aug; 21(8):2120-6. PubMed ID: 16611682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Furosemide absorption in patients with cirrhosis.
    Fredrick MJ; Pound DC; Hall SD; Brater DC
    Clin Pharmacol Ther; 1991 Mar; 49(3):241-7. PubMed ID: 2007318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of furosemide in gestosis of pregnancy.
    Riva E; Farina P; Tognoni G; Bottino S; Orrico C; Pardi G
    Eur J Clin Pharmacol; 1978 Dec; 14(5):361-6. PubMed ID: 729629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration.
    Garrett ER; Green JR; Bialer M
    Biopharm Drug Dispos; 1982; 3(2):129-64. PubMed ID: 7104462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of orally administered furosemide.
    Kelly MR; Cutler RE; Forrey AW; Kimpel BM
    Clin Pharmacol Ther; 1974 Feb; 15(2):178-86. PubMed ID: 4812154
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms.
    Rey E; d'Athis P; Richard MO; de Lauture D; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):62-7. PubMed ID: 7061180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of baclofen derived from intestinal infusion.
    Kochak GM; Rakhit A; Wagner WE; Honc F; Waldes L; Kershaw RA
    Clin Pharmacol Ther; 1985 Sep; 38(3):251-7. PubMed ID: 4028618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
    Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
    Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative bioavailability of two furosemide formulations in humans.
    Martin BK; Uihlein M; Ings RM; Stevens LA; McEwen J
    J Pharm Sci; 1984 Apr; 73(4):437-41. PubMed ID: 6726624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranitidine kinetics in normal subjects.
    Chau NP; Zech PY; Pozet N; Hadj-Aissa A
    Clin Pharmacol Ther; 1982 Jun; 31(6):770-4. PubMed ID: 6280919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.
    Uchino K; Isozaki S; Amano J; Tanaka N; Saitoh Y; Nakagawa F; Tamura Z; Oka H
    J Pharmacobiodyn; 1983 Sep; 6(9):684-91. PubMed ID: 6655548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study on furosemide disposition in man.
    Zhu JB; Koizumi T
    J Pharmacobiodyn; 1987 Aug; 10(8):370-6. PubMed ID: 3694431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.